{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth",
    "query": {
      "condition": "Growth"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1635,
    "total_pages": 164,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T00:21:42.413Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01295060",
      "title": "Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acromegaly"
      ],
      "interventions": [
        {
          "name": "Octreotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endo Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2011-02",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2013-09-20",
      "last_synced_at": "2026-05-22T00:21:42.413Z",
      "location_count": 6,
      "location_summary": "Denver, Colorado • Chicago, Illinois • Baltimore, Maryland + 3 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01295060"
    },
    {
      "nct_id": "NCT02357342",
      "title": "Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care intravitreal injections of anti-VEGF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Maturi, Raj K., M.D., P.C.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2015-04",
      "completion_date": "2017-01",
      "has_results": true,
      "last_update_posted_date": "2017-06-22",
      "last_synced_at": "2026-05-22T00:21:42.413Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02357342"
    },
    {
      "nct_id": "NCT02311322",
      "title": "Genetic Causes of Growth Disorders",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Short Stature",
        "Growth Disorder",
        "Syndromic Growth Disorder",
        "Tall Stature"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 334,
      "start_date": "2014-12-02",
      "completion_date": "2023-03-14",
      "has_results": false,
      "last_update_posted_date": "2023-03-16",
      "last_synced_at": "2026-05-22T00:21:42.413Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02311322"
    },
    {
      "nct_id": "NCT04952753",
      "title": "Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "NIS793",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Modified FOLFOX6",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 204,
      "start_date": "2021-11-15",
      "completion_date": "2025-01-20",
      "has_results": false,
      "last_update_posted_date": "2025-03-26",
      "last_synced_at": "2026-05-22T00:21:42.413Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04952753"
    },
    {
      "nct_id": "NCT04552730",
      "title": "Nerve Growth Factor for the Treatment of Cornea Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neurotrophic Keratitis"
      ],
      "interventions": [
        {
          "name": "Cenegermin-Bkbj",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2020-10-14",
      "completion_date": "2021-05-04",
      "has_results": false,
      "last_update_posted_date": "2021-12-14",
      "last_synced_at": "2026-05-22T00:21:42.413Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04552730"
    },
    {
      "nct_id": "NCT00719212",
      "title": "Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "AMG 479",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Translational Research in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 61,
      "start_date": "2009-01",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2016-01-11",
      "last_synced_at": "2026-05-22T00:21:42.413Z",
      "location_count": 16,
      "location_summary": "Bakersfield, California • Fullerton, California • La Verne, California + 10 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Verne",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00719212"
    },
    {
      "nct_id": "NCT00004061",
      "title": "Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Oral Complications"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "palifermin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 111,
      "start_date": "1999-05",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2013-06-26",
      "last_synced_at": "2026-05-22T00:21:42.413Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004061"
    },
    {
      "nct_id": "NCT07105228",
      "title": "Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinal Vasculitis"
      ],
      "interventions": [
        {
          "name": "aflibercept 2mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 290000,
      "start_date": "2025-07-15",
      "completion_date": "2025-09-15",
      "has_results": false,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-05-22T00:21:42.413Z",
      "location_count": 1,
      "location_summary": "Tarrytown, New York",
      "locations": [
        {
          "city": "Tarrytown",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07105228"
    },
    {
      "nct_id": "NCT01029665",
      "title": "Early Childhood Follow-up of Congenital Diaphragmatic Hernia Survivors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hernia, Diaphragmatic"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "4 Years to 6 Years"
      },
      "enrollment_count": 16,
      "start_date": "2008-09",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2024-04-12",
      "last_synced_at": "2026-05-22T00:21:42.413Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01029665"
    },
    {
      "nct_id": "NCT07581860",
      "title": "Growth Hormone Resistance of Beta-cells",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Healthy",
        "Obesity & Overweight",
        "Impaired Fasting Glucose (IFG)",
        "Impaired Glucose Tolerance (Prediabetes)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Missouri-Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 10,
      "start_date": "2026-08-01",
      "completion_date": "2030-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-05-22T00:21:42.413Z",
      "location_count": 1,
      "location_summary": "Columbia, Missouri",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07581860"
    }
  ]
}